In a filing, Celestica, Inc revealed its Former Officer Agrawal Alok K. acquired Company’s shares for reported $0.44 million on May 30 ’25. In the deal valued at $119.47 per share,3,672 shares were bought.
Then, Laurette Koellner bought 100,000 shares, generating $8,269,000 in total proceeds.
Before that, Laurette T Koellner bought 151,717 shares. Celestica, Inc shares valued at $13,945,827 were divested by the Director at a price of $91.92 per share.
JP Morgan initiated its Celestica, Inc [CLS] rating to an Overweight in a research note published on February 21, 2025; the price target was $166. CIBC also remained covering CLS and has increased its forecast on January 31, 2025 with a “Sector outperform” recommendation from previously “Neutral” rating. UBS started covering the stock on November 22, 2024. It rated CLS as “a Neutral”.
Price Performance Review of CLS
On Friday, Celestica, Inc [NYSE:CLS] saw its stock jump 1.19% to $120.73. Over the last five days, the stock has gained 4.64%. Celestica, Inc shares have risen nearly 30.80% since the year began. Nevertheless, the stocks have risen 129.05% over the past one year. While a 52-week high of $144.27 was reached on 02/05/25, a 52-week low of $40.25 was recorded on 04/04/25. SMA at 50 days reached $95.77, while 200 days put it at $86.63.
Levels Of Support And Resistance For CLS Stock
The 24-hour chart illustrates a support level at 118.53, which if violated will result in even more drops to 116.32. On the upside, there is a resistance level at 122.66. A further resistance level may holdings at 124.58. The Relative Strength Index (RSI) on the 14-day chart is 68.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.65, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 25.28%. Stochastics %K at 69.99% indicates the stock is a holding.
The most recent change occurred on November 05, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $91 price target.
